The Indian stock market witnessed another rough day on September 26, 2025, with both the Sensex and Nifty closing sharply lower. This marked the sixth straight session of losses, extending the ongoing market correction. Interestingly, the sell-off wasn’t triggered by domestic headlines—it was driven by a surprise trade policy move from the US.
For investors, especially those keeping an eye on pharma stocks and Pharma BeEs (an ETF tracking the Nifty Pharma Index), this raises the big question: Is this turbulence a risk or an opportunity?
What Triggered the Market Fall?
1. US Tariff Bomb on Pharma
The US administration announced a potential 100% tariff on branded and patented drug imports from countries including India, effective October 1.
Although India’s main strength lies in generic medicines (mostly exempt for now), panic set in. Big names such as Sun Pharma, Cipla, and Dr. Reddy’s faced sharp selling, as investors priced in risks to their US business revenue.
2. Collateral Damage Beyond Pharma
Export-driven sectors outside pharma—such as auto components and even niche product makers like Carysil—saw declines amid speculation of further tariff barriers.
3. Heavy FII Outflows
This shock only deepened the trend of Foreign Institutional Investor (FII) selling. On Sept 25, FIIs sold nearly ₹5,000 crore in equities, bringing September’s total to over ₹13,000 crore. Liquidity concerns and policy uncertainties are making FIIs cautious, leaving Domestic Institutional Investors (DIIs) to absorb the selling.
Market Impact on Sept 26
- Sensex fell by more than 700 points.
- Nifty slipped below 24,700, breaking a key support level.
- Pharma, IT, Auto, and Banking indices all closed in the red.
- The rupee weakened, hovering near its all-time low of ₹88.79 per dollar, heightening concerns about imported inflation.
The Unsung Hero: DIIs
Amid the foreign exit, DIIs have consistently stepped in to counterbalance the outflow. This stabilizing role highlights India’s evolving market structure—where domestic investors increasingly act as a safety net against external shocks.
What is Pharma BeEs?
For retail investors, the easiest way to get pharma exposure is often through Pharma BeEs.
- Pharma BeEs (ticker: PHARMABEES) is an Exchange Traded Fund (ETF) run by Nippon India.
- It tracks the Nifty Pharma Index, which consists of India’s leading pharmaceutical companies.
- Investors buying this ETF get broad sector exposure instead of betting on single pharma stocks.
- Top Holdings: Sun Pharma, Cipla, Dr. Reddy’s, Divi’s Labs, Lupin, Aurobindo Pharma, and Alkem Laboratories.
Recent Performance of Pharma BeEs
| Period | Performance | Notes |
|---|---|---|
| 1-Year | Around –1.9% | Reflects recent tariff worries & sector volatility. |
| Since Inception (2021) | ~7% annualized | Moderate growth considering global headwinds. |
| 52-Week Range | ₹19.47 – ₹24.65 | Shows significant swings. |
| Expense Ratio | ~0.19%–0.21% | Relatively cost-efficient ETF. |
In short: Pharma BeEs has struggled in the last year but remains a long-term play on India’s pharma sector.
Should You Invest in Pharma (and Pharma BeEs) Now?
Reasons to Stay Optimistic (Long-Term)
- Healthcare demand is rising due to government schemes, chronic diseases, and higher insurance coverage.
- India is the largest supplier of generics worldwide.
- Government incentives like the PLI scheme are boosting local manufacturing.
- Companies are investing in biosimilars, specialty drugs, and complex generics with higher margins.
Short-Term Risks
- US Tariff Uncertainty: May hurt companies with exposure to branded drugs.
- Regulatory Scrutiny: US FDA plant inspections remain a risk factor.
- Global Pricing Pressure: Intense price competition can squeeze margins.
The Sept 26 market fall showed how global shocks can rattle Indian equities. For pharma, the near-term looks shaky, but the long-term growth story remains intact.
Pharma BeEs offers a simple, diversified entry point into India’s pharma sector. While the ETF has seen short-term pressure, it remains well-positioned to benefit from the structural growth of healthcare demand in India and beyond.
For investors, the message is clear: don’t panic sell, stay selective, and think long-term.
